Novocure Ltd., Haifa, Israel
2 ARTICLES PUBLISHED IN JoVE
Cancer Research
Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields)
Yaara Porat 1, Moshe Giladi 1, Rosa S. Schneiderman 1, Roni Blat 1, Anna Shteingauz 1, Einav Zeevi 1, Mijal Munster 1, Tali Voloshin 1, Noa Kaynan 1, Orna Tal 1, Eilon D. Kirson 2, Uri Weinberg 3, Yoram Palti 2
1Preclinical Research Department, Novocure Ltd., Haifa, Israel, 2Novocure Ltd., Haifa, Israel, 3Novocure GmbH, Lucerne, Switzerland
Tumor Treating Fields (TTFields) are an effective anti-tumor treatment modality delivered via the continuous, noninvasive application of low-intensity, intermediate-frequency, alternating electric fields. TTFields application to cell lines using a TTFields in vitro application system allows for the determination of the optimal frequency that leads to the highest reduction in cell counts.
Immunology and Infection
Overexpression and Purification of Human Cis-prenyltransferase in Escherichia coli
Ilan Edri *1, Michal Goldenberg *1, Michal Lisnyansky 2, Roi Strulovich 2, Hadas Newman 1,3, Anat Loewenstein 1,3, Daniel Khananshvili 2, Moshe Giladi 2,4, Yoni Haitin 2
1Sackler Faculty of Medicine, Tel Aviv University, 2Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, 3Department of Ophthalmology, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, 4Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University
A simple protocol for overexpression and purification of codon-optimized, human cis-prenyltransferase, under non-denaturing conditions, from Escherichia coli, is described, along with an enzymatic activity assay. This protocol can be generalized for production of other cis- prenyltransferase proteins in quantity and quality suitable for mechanistic studies.
